| pubmed-article:1647182 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1647182 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:1647182 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:1647182 | lifeskim:mentions | umls-concept:C0007131 | lld:lifeskim |
| pubmed-article:1647182 | lifeskim:mentions | umls-concept:C0002475 | lld:lifeskim |
| pubmed-article:1647182 | lifeskim:mentions | umls-concept:C0020823 | lld:lifeskim |
| pubmed-article:1647182 | lifeskim:mentions | umls-concept:C0205329 | lld:lifeskim |
| pubmed-article:1647182 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:1647182 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:1647182 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:1647182 | pubmed:dateCreated | 1991-8-1 | lld:pubmed |
| pubmed-article:1647182 | pubmed:abstractText | 42 patients with progressive and advanced non-small cell lung cancer received chemotherapy comprising ifosfamide 1.5 g/m2, mesna 1.5 g/m2 and mitomycin 1.2 mg/m2 daily for 5 days. Only those patients with symptoms and progressive disease were selected for treatment. Partial response was achieved in 10/42 patients (23.8%) and stable disease in 25/42 (59.5%). The Karnofsky performance status (KP) improved in 10/42 patients (23.8%) and a subjective respiratory symptom score improved in 12 patients (28.6%). In addition 27 patients (64.3%) had stabilisation of both the KP and respiratory score following chemotherapy. These results indicate that the ifosfamide and mitomycin combination is active in non-small cell lung cancer in this selected group of patients with antitumour and symptom control activity. | lld:pubmed |
| pubmed-article:1647182 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1647182 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1647182 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1647182 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1647182 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1647182 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1647182 | pubmed:issn | 0959-8049 | lld:pubmed |
| pubmed-article:1647182 | pubmed:author | pubmed-author:ThatcherNN | lld:pubmed |
| pubmed-article:1647182 | pubmed:author | pubmed-author:GurnerAA | lld:pubmed |
| pubmed-article:1647182 | pubmed:author | pubmed-author:KamthanAA | lld:pubmed |
| pubmed-article:1647182 | pubmed:author | pubmed-author:DodwellDD | lld:pubmed |
| pubmed-article:1647182 | pubmed:author | pubmed-author:de CamposE... | lld:pubmed |
| pubmed-article:1647182 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1647182 | pubmed:volume | 27 | lld:pubmed |
| pubmed-article:1647182 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1647182 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1647182 | pubmed:pagination | 565-8 | lld:pubmed |
| pubmed-article:1647182 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1647182 | pubmed:meshHeading | pubmed-meshheading:1647182-... | lld:pubmed |
| pubmed-article:1647182 | pubmed:meshHeading | pubmed-meshheading:1647182-... | lld:pubmed |
| pubmed-article:1647182 | pubmed:meshHeading | pubmed-meshheading:1647182-... | lld:pubmed |
| pubmed-article:1647182 | pubmed:meshHeading | pubmed-meshheading:1647182-... | lld:pubmed |
| pubmed-article:1647182 | pubmed:meshHeading | pubmed-meshheading:1647182-... | lld:pubmed |
| pubmed-article:1647182 | pubmed:meshHeading | pubmed-meshheading:1647182-... | lld:pubmed |
| pubmed-article:1647182 | pubmed:meshHeading | pubmed-meshheading:1647182-... | lld:pubmed |
| pubmed-article:1647182 | pubmed:meshHeading | pubmed-meshheading:1647182-... | lld:pubmed |
| pubmed-article:1647182 | pubmed:meshHeading | pubmed-meshheading:1647182-... | lld:pubmed |
| pubmed-article:1647182 | pubmed:meshHeading | pubmed-meshheading:1647182-... | lld:pubmed |
| pubmed-article:1647182 | pubmed:meshHeading | pubmed-meshheading:1647182-... | lld:pubmed |
| pubmed-article:1647182 | pubmed:meshHeading | pubmed-meshheading:1647182-... | lld:pubmed |
| pubmed-article:1647182 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1647182 | pubmed:articleTitle | Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer. | lld:pubmed |
| pubmed-article:1647182 | pubmed:affiliation | Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester, U.K. | lld:pubmed |
| pubmed-article:1647182 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1647182 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
